FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTORNEY DOCKET NO. PU4804USW	SERIAL NO. 10/543,046
	APPLICANT: SHEWCHUK, et al.	
	FILING DATE:7/21/05	GROUP

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes / No

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

/DJS/	1	Johnson, et al., Cell, 85:149-158
	2	Cox, et al., Curr. Opin. Struct. Biol., 4: 893-901
/DJS/	3	M. Shahinpoor and K. J. Kim, "Ionic polymer-metal composites: I. Fundamentals", Smart Mater. Struct. 10:4, pp. 819-833, (August 2001).
/DJS/	4	Mohammadi, et al., "Stucture of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism," Cell, 1996, V86, pp. 577-87.
/DJS/	5	Wybenga-Groot et al., "Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region," Cell, 2001, V106, pp. 745-757.
/DJS/	6	Hubbard, S.R., "Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog," 1997, Embo J., V16, pp. 5572-5581.
/DJS/	7	Hubbard et al., "Crystal structure of the tyrosine kinase domain of the human insulin receptor, Nature, 1994, V372, pp. 746-754.
/DJS/	8	McTigue, et al., "Crystal structure of the kinase domain of human vascular endothelial growth factor receptor 2: a key enzyme in angiogenesis, Structure, 1999, V7, pp. 319-330.
/DJS/	9	Xu et al., "Crystal structures of c-Src reveal features of its autoinhibitory mechanism, Mol. Cell, 1999, V3(5), pp. 629-38.
/DJS/	10	Bouyain et al., "The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand," Proc. Natl. Acad. Sci., 2005, v102 N42, pp. 15024-15029.

Continue on page

EXAMINER /David Steadman/	DATE CONSIDERED 05/21/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.